Cargando…
AF.51 VEDOLIZUMAB MAY BE AN EFFECTIVE OPTION FOR THE MANAGEMENT OF POSTOPERATIVE RECURRENCE OF CROHN’S DISEASE
| Autores principales: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Editrice Gastroenterologica Italiana S.r.l.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451194/ http://dx.doi.org/10.1016/S1590-8658(21)00614-9 |
| _version_ | 1784569791144525824 |
|---|---|
| author | Macaluso, F.S. Cappello, M. Crispino, F. Grova, M. Privitera, A.C. Piccillo, G. Magnano, A. Ferracane, C. Belluardo, N. Giangreco, E. Fries, W. Viola, A. Di Mitri, R. Mocciaro, F. Camilleri, S. Garufi, S. Renna, S. Casà, A. Maida, M. Orlando, A. |
| author_facet | Macaluso, F.S. Cappello, M. Crispino, F. Grova, M. Privitera, A.C. Piccillo, G. Magnano, A. Ferracane, C. Belluardo, N. Giangreco, E. Fries, W. Viola, A. Di Mitri, R. Mocciaro, F. Camilleri, S. Garufi, S. Renna, S. Casà, A. Maida, M. Orlando, A. |
| author_sort | Macaluso, F.S. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8451194 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Editrice Gastroenterologica Italiana S.r.l. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-84511942021-09-20 AF.51 VEDOLIZUMAB MAY BE AN EFFECTIVE OPTION FOR THE MANAGEMENT OF POSTOPERATIVE RECURRENCE OF CROHN’S DISEASE Macaluso, F.S. Cappello, M. Crispino, F. Grova, M. Privitera, A.C. Piccillo, G. Magnano, A. Ferracane, C. Belluardo, N. Giangreco, E. Fries, W. Viola, A. Di Mitri, R. Mocciaro, F. Camilleri, S. Garufi, S. Renna, S. Casà, A. Maida, M. Orlando, A. Dig Liver Dis Abstracts of the 27th National Congress of Digestive Diseases 2021 – FISMAD Editrice Gastroenterologica Italiana S.r.l. 2021-09 2021-09-20 /pmc/articles/PMC8451194/ http://dx.doi.org/10.1016/S1590-8658(21)00614-9 Text en Copyright © 2021 Editrice Gastroenterologica Italiana S.r.l. All rights reserved. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Abstracts of the 27th National Congress of Digestive Diseases 2021 – FISMAD Macaluso, F.S. Cappello, M. Crispino, F. Grova, M. Privitera, A.C. Piccillo, G. Magnano, A. Ferracane, C. Belluardo, N. Giangreco, E. Fries, W. Viola, A. Di Mitri, R. Mocciaro, F. Camilleri, S. Garufi, S. Renna, S. Casà, A. Maida, M. Orlando, A. AF.51 VEDOLIZUMAB MAY BE AN EFFECTIVE OPTION FOR THE MANAGEMENT OF POSTOPERATIVE RECURRENCE OF CROHN’S DISEASE |
| title | AF.51 VEDOLIZUMAB MAY BE AN EFFECTIVE OPTION FOR THE MANAGEMENT OF POSTOPERATIVE RECURRENCE OF CROHN’S DISEASE |
| title_full | AF.51 VEDOLIZUMAB MAY BE AN EFFECTIVE OPTION FOR THE MANAGEMENT OF POSTOPERATIVE RECURRENCE OF CROHN’S DISEASE |
| title_fullStr | AF.51 VEDOLIZUMAB MAY BE AN EFFECTIVE OPTION FOR THE MANAGEMENT OF POSTOPERATIVE RECURRENCE OF CROHN’S DISEASE |
| title_full_unstemmed | AF.51 VEDOLIZUMAB MAY BE AN EFFECTIVE OPTION FOR THE MANAGEMENT OF POSTOPERATIVE RECURRENCE OF CROHN’S DISEASE |
| title_short | AF.51 VEDOLIZUMAB MAY BE AN EFFECTIVE OPTION FOR THE MANAGEMENT OF POSTOPERATIVE RECURRENCE OF CROHN’S DISEASE |
| title_sort | af.51 vedolizumab may be an effective option for the management of postoperative recurrence of crohn’s disease |
| topic | Abstracts of the 27th National Congress of Digestive Diseases 2021 – FISMAD |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451194/ http://dx.doi.org/10.1016/S1590-8658(21)00614-9 |
| work_keys_str_mv | AT macalusofs af51vedolizumabmaybeaneffectiveoptionforthemanagementofpostoperativerecurrenceofcrohnsdisease AT cappellom af51vedolizumabmaybeaneffectiveoptionforthemanagementofpostoperativerecurrenceofcrohnsdisease AT crispinof af51vedolizumabmaybeaneffectiveoptionforthemanagementofpostoperativerecurrenceofcrohnsdisease AT grovam af51vedolizumabmaybeaneffectiveoptionforthemanagementofpostoperativerecurrenceofcrohnsdisease AT priviteraac af51vedolizumabmaybeaneffectiveoptionforthemanagementofpostoperativerecurrenceofcrohnsdisease AT piccillog af51vedolizumabmaybeaneffectiveoptionforthemanagementofpostoperativerecurrenceofcrohnsdisease AT magnanoa af51vedolizumabmaybeaneffectiveoptionforthemanagementofpostoperativerecurrenceofcrohnsdisease AT ferracanec af51vedolizumabmaybeaneffectiveoptionforthemanagementofpostoperativerecurrenceofcrohnsdisease AT belluardon af51vedolizumabmaybeaneffectiveoptionforthemanagementofpostoperativerecurrenceofcrohnsdisease AT giangrecoe af51vedolizumabmaybeaneffectiveoptionforthemanagementofpostoperativerecurrenceofcrohnsdisease AT friesw af51vedolizumabmaybeaneffectiveoptionforthemanagementofpostoperativerecurrenceofcrohnsdisease AT violaa af51vedolizumabmaybeaneffectiveoptionforthemanagementofpostoperativerecurrenceofcrohnsdisease AT dimitrir af51vedolizumabmaybeaneffectiveoptionforthemanagementofpostoperativerecurrenceofcrohnsdisease AT mocciarof af51vedolizumabmaybeaneffectiveoptionforthemanagementofpostoperativerecurrenceofcrohnsdisease AT camilleris af51vedolizumabmaybeaneffectiveoptionforthemanagementofpostoperativerecurrenceofcrohnsdisease AT garufis af51vedolizumabmaybeaneffectiveoptionforthemanagementofpostoperativerecurrenceofcrohnsdisease AT rennas af51vedolizumabmaybeaneffectiveoptionforthemanagementofpostoperativerecurrenceofcrohnsdisease AT casaa af51vedolizumabmaybeaneffectiveoptionforthemanagementofpostoperativerecurrenceofcrohnsdisease AT maidam af51vedolizumabmaybeaneffectiveoptionforthemanagementofpostoperativerecurrenceofcrohnsdisease AT orlandoa af51vedolizumabmaybeaneffectiveoptionforthemanagementofpostoperativerecurrenceofcrohnsdisease |